Outlook Therapeutics Inc (OTLK)

Oct 13, 2026

Two reported owners share voting power over a stake above 5% in Outlook Therapeutics (OTLK). - Stock Titan

Oct 13, 2026

Oct 11, 2026

Certain Common Stock of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-OCT-2026. - www.marketscreener.com

Oct 11, 2026

Oct 11, 2026

Outlook Therapeutics (Nasdaq:OTLK)Stock Analysis - Simply Wall Street

Oct 11, 2026

Oct 05, 2026

Outlook Therapeutics files CMS code application and Outlook Therapeutics stock trades at EUR 0.53 - AD HOC NEWS

Oct 05, 2026

Sep 30, 2026

Outlook Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView

Sep 30, 2026

Sep 12, 2026

Outlook Therapeutics at H.C. Wainwright: launch hinges on access By Investing.com - Investing.com Australia

Sep 12, 2026

Sep 12, 2026

Outlook Therapeutics at H.C. Wainwright: launch hinges on access By Investing.com - Investing.com Canada

Sep 12, 2026

Sep 11, 2026

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand - The Manila Times

Sep 11, 2026

Sep 11, 2026

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand - marketscreener.com

Sep 11, 2026

Sep 11, 2026

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand - Yahoo Finance

Sep 11, 2026

Sep 11, 2026

OTLK Maintained by Ascendiant Capital -- Price Target Raised to $10.50 - GuruFocus

Sep 11, 2026

Sep 10, 2026

Outlook Therapeutics Inc. (OTLK) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com

Sep 10, 2026

Sep 10, 2026

Outlook Therapeutics CEO discusses LYTENAVA commercial launch By Investing.com - Investing.com Australia

Sep 10, 2026

Sep 10, 2026

Outlook Therapeutics CEO discusses LYTENAVA commercial launch By Investing.com - Investing.com Nigeria

Sep 10, 2026

Sep 10, 2026

Outlook Therapeutics CEO discusses LYTENAVA commercial launch - investing.com

Sep 10, 2026

Sep 10, 2026

Outlook Therapeutics CEO discusses LYTENAVA commercial launch By Investing.com - Investing.com Canada

Sep 10, 2026

Sep 10, 2026

Outlook Therapeutics CEO discusses LYTENAVA commercial launch By Investing.com - Investing.com UK

Sep 10, 2026

Sep 10, 2026

Only one FDA-approved eye medicine of its type exists in the U.S. It’s LYTENAVA. - Stock Titan

Sep 10, 2026

Sep 07, 2026

AMZN: Amazon.com Inc Latest Stock Price, Analysis, News and Trading Ideas - stocktwits.com

Sep 07, 2026

Sep 03, 2026

People on the Move: Kevin Lundquist Named Chief Financial Officer of Outlook Therapeutics - BioBuzz

Sep 03, 2026

Sep 02, 2026

CFO at Outlook Therapeutics (NASDAQ: OTLK) gets 500,000 hiring options - Stock Titan

Sep 02, 2026

Sep 02, 2026

Outlook Therapeutics (NASDAQ: OTLK) CFO reports zero insider holdings - stocktitan.net

Sep 02, 2026

Aug 28, 2026

Outlook Therapeutics Announces CFO Transition and Board Change - The Globe and Mail

Aug 28, 2026

Aug 28, 2026

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™ - Sahm

Aug 28, 2026

Aug 28, 2026

Outlook Therapeutics Names Kevin Lundquist CFO Ahead of Lytenava U.S. Launch - VisionMonday.com

Aug 28, 2026

Aug 28, 2026

Outlook Therapeutics Names Kevin Lundquist CFO Ahead of Lytenava U.S. Launch - visionmonday.com

Aug 28, 2026

Aug 27, 2026

Outlook Therapeutics appoints Kevin Lundquist as CFO as Lawrence Kenyon to depart - TradingView

Aug 27, 2026

Aug 27, 2026

Outlook Therapeutics Appoints Kevin Lundquist as Chief - GlobeNewswire

Aug 27, 2026

Aug 27, 2026

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference - marketscreener.com

Aug 27, 2026

Aug 27, 2026

Outlook Therapeutics hires a CFO for its only FDA-approved eye version of bevacizumab - stocktitan.net

Aug 27, 2026

Aug 19, 2026

Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo

Aug 19, 2026

Aug 19, 2026

Nasdaq Futures Lead US Premarket Rally As Iran Ceasefire Reports Ease Fears Ahead Of Big Tech Earnings: Why NVDA, ORCL, SPCX, XOM, OTLK Are In Focus - Stocktwits

Aug 19, 2026

Aug 19, 2026

Outlook Therapeutics (OTLK) investor held to 9.99% cap - Stock Titan

Aug 19, 2026

Aug 19, 2026

Outlook Therapeutics Inc (OTLK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Aug 19, 2026

Aug 18, 2026

Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo

Aug 18, 2026

Aug 18, 2026

Outlook Therapeutics, Inc. 2026: Revenue $8.7K, EPS ($0.15) — 10-Q Summary - TradingView

Aug 18, 2026

Aug 18, 2026

Outlook Therapeutics (OTLK) wins FDA exclusivity but holds limited cash - Stock Titan

Aug 18, 2026

Aug 18, 2026

Brookline Capital cuts Outlook Therapeutics stock price target on model update - Investing.com

Aug 18, 2026

Aug 18, 2026

Brookline Capital cuts Outlook Therapeutics stock price target on model update - Investing.com

Aug 18, 2026

Aug 18, 2026

Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo

Aug 18, 2026

Aug 17, 2026

Outlook Therapeutics delays quarterly SEC filing - TipRanks

Aug 17, 2026

Aug 17, 2026

META_TITLE_QUOTE - Yahoo Finance

Aug 17, 2026

Aug 17, 2026

OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp - Yahoo Finance

Aug 17, 2026

Aug 17, 2026

OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp - Zacks Investment Research

Aug 17, 2026

Aug 17, 2026

Outlook Therapeutics Insider Bought Shares Worth $2,499,999, According to a Recent SEC Filing - marketscreener.com

Aug 17, 2026

Aug 17, 2026

Outlook Therapeutics Insider Bought Shares Worth $2,499,999, According to a Recent SEC Filing - moomoo.com

Aug 17, 2026

Aug 17, 2026

Outlook Therapeutics, Inc. SEC Filing (Aug 17, 2026) | OTLK NT 10-Q - Stock Titan

Aug 17, 2026

Aug 17, 2026

Outlook Therapeutics Posts Q3 Financials, Raises Funds for Lytenava Launch - visionmonday.com

Aug 17, 2026

Aug 16, 2026

Outlook Therapeutics Inc (OTLK) Stock News Today - TradingKey

Aug 16, 2026

Aug 16, 2026

MSN Money - MSN

Aug 16, 2026